Treating Patients with Complex Metabolic Conditions

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Year Invested: 2011
Location: Newton, Mass.

Recent News

August 7, 2018
Allena Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference

August 7, 2018
Allena Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

July 23, 2018
Allena Pharmaceuticals Announces First Patients Treated in Phase 2 Basket Study of ALLN-177 in Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Advanced Chronic Kidney Disease

Read More News

Associated Team Members

Robert Tepper, M.D.